Biolinq bags FDA okay for autonomous glucose sensor Biolinq gets an FDA green light for its autonomous, needle-free continuous glucose monitor, plus a round-up of other medtech developments.

Wearable technology developer #Biolinq has won FDA authorisation for a #biosensor that can measure #glucose levels continuously just beneath the skin's surface, without the need for a needle.

pharmaphorum.com/news/biolinq...

Funding Raises: #Chainguard $356M Series D; #Supabase $200M Series D; #Electra $186M Series B; #CarisLifeSciences $168M; #Ocient $132M Series B; #Flow $100M Series B; #Biolinq $100M Series C; #EndorLabs $93M Series B; #Noxtua €80.7M Series B; #Yulu $80M Series C